Press Releases Aclaris Therapeutics, Inc.

Equities

ACRS

US00461U1051

Real-time Estimate Cboe BZX Other stock markets 10:45:32 2024-04-29 am EDT			5-day change	1st Jan Change
1.215 ^USD	+1.25%		0.00%	+16.19%

Mar. 19	Aclaris Therapeutics, Inc. Announces Board Resignations	CI
Feb. 27	Aclaris Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FLARE THERAPEUTICS APPOINTS DOUGLAS MANION, M.D., FRCP AS CHIEF EXECUTIVE OFFICER	Apr. 24	AQ
Aclaris: Q4 Earnings Snapshot	Feb. 27	AQ
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update	Feb. 27	AQ
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review	Jan. 16	AQ
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis	Jan. 10	AQ
Aclaris Therapeutics Provides Corporate Update	Dec. 19	AQ
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia	Dec. 05	AQ
Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update	Nov. 13	AQ
Cryopyrin-Associated Periodic Syndrome Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	Nov. 13	AQ
Aclaris: Q3 Earnings Snapshot	Nov. 06	AQ
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update	Nov. 06	AQ
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis	23-10-04	AQ
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)	23-10-03	AQ
Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference	23-09-20	AQ
Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor	23-09-18	AQ
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update	23-08-07	AQ
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)	23-06-13	AQ
Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences	23-06-05	AQ
Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences	23-06-02	AQ
Aclaris Therapeutics : Therpeutics Q1 2023 Financial Results Presentation	23-05-08	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Aclaris Therapeutics, Inc.

Equities

ACRS

US00461U1051

Press Releases

Filters